David Han, MD
Family Medicine · Glendale, CANPI 1093755977
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,556 of the $6,773 with a category attached, or 82.0%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,997 and has fallen 68.1% since, to $637 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Abbott$1K
- AbbVie$1K
- Boehringer Ingelheim$474
- GSK$292
- plus $612 from 8 others
Across 53 payments — averaging $42,615 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$1.2M
- Sanofi US Services Inc.$851K
- Astrazeneca UK Limited$144K
- Amgen$21K
- Pfizer$16K
- AstraZeneca$15K
- plus $32K from 5 others
What the payments were for
- Consulting fees$1,20018%
- Travel & lodging$170%
- Food & beverage$5,55682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $1,488 |
| Biohaven Pharmaceuticals, Inc. | 8 | $1,358 |
| Abbott | 62 | $1,285 |
| AbbVie(2 entities) | 40 | $1,263 |
| Boehringer Ingelheim | 17 | $474 |
| GSK | 13 | $292 |
| Amgen | 5 | $132 |
| Astellas Pharma US Inc | 6 | $108 |
| Pfizer | 4 | $99 |
| Amarin Pharma, Inc. | 4 | $84 |
| Lilly USA, LLC | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- Xultophy 100/3.6$244
- Ozempic$242
- FREESTYLE LIBRE 3$141
- Tresiba$125
- VIBERZI$125
- FreeStyle Libre Pro$124
- RYBELSUS$124
- Creon$121
How this compares
$6,773 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $64,436 |
| EliquisApixaban | 39 | $48,713 |
| CreonLipase/Protease/Amylase | 32 | $45,900 |
| XareltoRivaroxaban | 25 | $39,134 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $35,245 |
| JanuviaSitagliptin Phosphate | 20 | $31,328 |
| RybelsusSemaglutide | 15 | $30,085 |
| Repatha SureclickEvolocumab | 16 | $26,416 |
| RestasisCyclosporine | 14 | $24,375 |
| TradjentaLinagliptin | 26 | $24,168 |
| VascepaIcosapent Ethyl | 52 | $22,754 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $21,378 |
| ProliaDenosumab | 12 | $19,723 |
| OzempicSemaglutide | 19 | $18,742 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $14,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $474 | $103,399102 claims |
| AbbVieCreon, Restasis, Synthroid | $1,263 | $72,27961 claims |
| PfizerEliquis, Paxlovid | $99 | $50,14381 claims |
| Novo NordiskRybelsus, Ozempic | $1,488 | $48,82734 claims |
| GSKTrelegy Ellipta | $292 | $35,24521 claims |
| AmgenProlia | $132 | $19,72312 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $12,32313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Glendale
- Narineh ArutyounianGlendale$76K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.